
## Simon P L Travis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3683901/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut, 2012, 61, 1693-1700.	12.1	1,295
2	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. Journal of Crohn's and Colitis, 2010, 4, 28-62.	1.3	1,247
3	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. Journal of Crohn's and Colitis, 2012, 6, 991-1030.	1.3	1,106
4	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Journal of Crohn's and Colitis, 2010, 4, 7-27.	1.3	1,050
5	Guidelines for the management of inflammatory bowel disease in adults. Gut, 2004, 53, v1-v16.	12.1	914
6	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. Journal of Crohn's and Colitis, 2012, 6, 965-990.	1.3	715
7	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. Journal of Crohn's and Colitis, 2010, 4, 63-101.	1.3	695
8	Mucosal healing in inflammatory bowel diseases: a systematic review. Gut, 2012, 61, 1619-1635.	12.1	673
9	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet, The, 2017, 390, 2779-2789.	13.7	633
10	IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease. Journal of Experimental Medicine, 2011, 208, 1127-1133.	8.5	572
11	Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease. Nature Medicine, 2017, 23, 579-589.	30.7	571
12	The Diagnostic Approach to Monogenic Very Early Onset Inflammatory Bowel Disease. Gastroenterology, 2014, 147, 990-1007.e3.	1.3	559
13	European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut, 2006, 55, i16-i35.	12.1	533
14	Development of the Crohn's disease digestive damage score, the Lémann score. Inflammatory Bowel Diseases, 2011, 17, 1415-1422.	1.9	496
15	European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. Journal of Crohn's and Colitis, 2008, 2, 1-23.	1.3	470
16	Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut, 2012, 61, 535-542.	12.1	463
17	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. Journal of Crohn's and Colitis, 2013, 7, 1-33.	1.3	422
18	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?. American Journal of Gastroenterology, 2011, 106, 199-212.	0.4	356

#	Article	IF	CITATIONS
19	Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity. Gastroenterology, 2013, 145, 987-995.	1.3	354
20	Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6â€years of follow-up. Gut, 2016, 65, 408-414.	12.1	339
21	Development and validation of the Nancy histological index for UC. Gut, 2017, 66, 43-49.	12.1	322
22	The pattern and outcome of acute severe colitis. Journal of Crohn's and Colitis, 2010, 4, 431-437.	1.3	276
23	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell, 2021, 184, 5699-5714.e11.	28.9	262
24	Systematic review: Histological remission in inflammatory bowel disease. Is â€~complete' remission the new treatment paradigm? An IOIBD initiative. Journal of Crohn's and Colitis, 2014, 8, 1582-1597.	1.3	235
25	Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut, 2014, 63, 433-441.	12.1	222
26	Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study. Gastroenterology, 2012, 143, 1218-1226.e2.	1.3	213
27	Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet, The, 2015, 386, 137-144.	13.7	207
28	Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. British Journal of Surgery, 2010, 97, 404-409.	0.3	202
29	Conventional Medical Management of Inflammatory Bowel Disease. Gastroenterology, 2011, 140, 1827-1837.e2.	1.3	200
30	The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis. Gastroenterology, 2013, 145, 149-157.e2.	1.3	196
31	Review article: defining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2011, 34, 113-124.	3.7	180
32	Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. The Lancet Gastroenterology and Hepatology, 2016, 1, 15-24.	8.1	176
33	Current best practice for disease activity assessment in IBD. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 567-579.	17.8	169
34	5-aminosalicylic acids and the risk of renal disease: A large British epidemiologic studyâ~†. Gastroenterology, 2004, 126, 1733-1739.	1.3	154
35	Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 548-558.	8.1	143
36	Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease. JAMA - Journal of the American Medical Association, 2015, 314, 2524.	7.4	136

#	Article	IF	CITATIONS
37	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. Gastroenterology, 2020, 159, 139-147.	1.3	126
38	IL-1-driven stromal–neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. Nature Medicine, 2021, 27, 1970-1981.	30.7	117
39	Outcome measurement in clinical trials for ulcerative colitis: towards standardisation. Trials, 2007, 8, 17.	1.6	113
40	Reduced sodium/proton exchanger NHE3 activity causes congenital sodium diarrhea. Human Molecular Genetics, 2015, 24, 6614-6623.	2.9	111
41	Development of an index to define overall disease severity in IBD. Gut, 2018, 67, 244-254.	12.1	108
42	Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Alimentary Pharmacology and Therapeutics, 2017, 45, 801-813.	3.7	106
43	Association Between the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Outcomes in Acute Severe Ulcerative Colitis. Journal of Crohn's and Colitis, 2015, 9, 376-381.	1.3	104
44	Analysis of the Gut Microbiome of Rural and Urban Healthy Indians Living in Sea Level and High Altitude Areas. Scientific Reports, 2018, 8, 10104.	3.3	104
45	Rdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative Colitis. Inflammatory Bowel Diseases, 2005, 11, 713-719.	1.9	103
46	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease—an International, Cross-disciplinary Consensus. Journal of Crohn's and Colitis, 2018, 12, 408-418.	1.3	102
47	Mucosal Healing As a Target of Therapy for Colonic Inflammatory Bowel Disease and Methods to Score Disease Activity. Gastrointestinal Endoscopy Clinics of North America, 2014, 24, 367-378.	1.4	101
48	Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 3-15.	3.7	97
49	Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflammatory Bowel Diseases, 2009, 15, 1599-1604.	1.9	93
50	Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut, 2011, 60, 3-9.	12.1	93
51	Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2016, 1, 273-282.	8.1	91
52	Comparing disease activity indices in ulcerative colitis. Journal of Crohn's and Colitis, 2014, 8, 318-325.	1.3	89
53	Acute variceal haemorrhage in the United Kingdom: Patient characteristics, management and outcomes in a nationwide audit. Digestive and Liver Disease, 2014, 46, 419-426.	0.9	81
54	Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. Journal of Crohn's and Colitis, 2015, 9, 601-606.	1.3	81

#	Article	IF	CITATIONS
55	Clinical Genomics for the Diagnosis of Monogenic Forms of Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2021, 72, 456-473.	1.8	79
56	Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory TÂcells. Journal of Allergy and Clinical Immunology, 2017, 139, 607-620.e15.	2.9	77
57	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety. American Journal of Gastroenterology, 2011, 106, 1594-1602.	0.4	71
58	NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. Mucosal Immunology, 2018, 11, 562-574.	6.0	71
59	Long-term outcome after admission for acute severe ulcerative colitis in Oxford: The 1992–1993 cohort. Inflammatory Bowel Diseases, 2009, 15, 823-828.	1.9	70
60	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 399-406.	8.1	70
61	The role of CMV in steroid-resistant ulcerative colitis: A systematic review. Journal of Crohn's and Colitis, 2009, 3, 141-148.	1.3	60
62	Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance. Gut, 2021, 70, 1023-1036.	12.1	58
63	Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open, 2015, 5, e007230-e007230.	1.9	57
64	Conventional drug therapy for inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2015, 50, 90-112.	1.5	57
65	Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis—a Prospective Analysis. Journal of Crohn's and Colitis, 2019, 13, 424-430.	1.3	54
66	Introducing Vedolizumab to Clinical Practice: Who, When, and How?. Journal of Crohn's and Colitis, 2015, 9, 356-366.	1.3	53
67	Obesity in Inflammatory Bowel Disease: Gains in Adiposity despite High Prevalence of Myopenia and Osteopenia. Nutrients, 2018, 10, 1192.	4.1	53
68	Loss of IL-10 signaling in macrophages limits bacterial killing driven by prostaglandin E2. Journal of Experimental Medicine, 2020, 217, .	8.5	51
69	The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. Journal of Crohn's and Colitis, 2015, 9, 607-616.	1.3	50
70	Faecal Calprotectin and UCEIS Predict Short-term Outcomes in Acute Severe Colitis: Prospective Cohort Study. Journal of Crohn's and Colitis, 2017, 11, 1309-1316.	1.3	46
71	The Management of Acute Severe Colitis: ACPGBI Position Statement. Colorectal Disease, 2008, 10, 8-29.	1.4	45
72	Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. Journal of Crohn's and Colitis, 2013, 7, e449-e456.	1.3	45

#	Article	IF	CITATIONS
73	Outcomes after ileal pouch anal anastomosis in patients with primary sclerosing cholangitis. Journal of Crohn's and Colitis, 2014, 8, 662-670.	1.3	45
74	The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. Journal of Crohn's and Colitis, 2020, 14, 192-204.	1.3	45
75	Th1 and Innate Lymphoid Cells Accumulate in Primary Sclerosing Cholangitis-associated Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2017, 11, 1124-1134.	1.3	43
76	Review article: induction therapy for patients with active ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2006, 24, 10-16.	3.7	40
77	Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data. Journal of Crohn's and Colitis, 2017, 11, jjw187.	1.3	40
78	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. Journal of Crohn's and Colitis, 2016, 10, 607-618.	1.3	39
79	Visceral Adipose Tissue Is Associated With Stricturing Crohn's Disease Behavior, Fecal Calprotectin, and Quality of Life. Inflammatory Bowel Diseases, 2019, 25, 592-600.	1.9	39
80	Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom. Transfusion, 2013, 53, 1069-1076.	1.6	38
81	Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease. Nature Communications, 2020, 11, 995.	12.8	37
82	Head-to-head trials in inflammatory bowel disease: past, present and future. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 365-376.	17.8	37
83	Obstructing giant post-inflammatory polyposis in ulcerative colitis: Case report and review of the literature. Journal of Crohn's and Colitis, 2008, 2, 170-180.	1.3	36
84	METRIC (MREnterography or ulTRasound in Crohn's disease): a study protocol for a multicentre, non-randomised, single-arm, prospective comparison study of magnetic resonance enterography and small bowel ultrasound compared to a reference standard in those aged 16 and over. BMC Gastroenterology, 2014, 14, 142.	2.0	36
85	Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. Journal of Crohn's and Colitis, 2017, 11, 1317-1325.	1.3	35
86	Plasma Nuclear Magnetic Resonance Metabolomics Discriminates Between High and Low Endoscopic Activity and Predicts Progression in a Prospective Cohort of Patients With Ulcerative Colitis. Journal of Crohn's and Colitis, 2018, 12, 1326-1337.	1.3	35
87	Limited uptake of ulcerative colitis "treatâ€toâ€target―recommendations in realâ€world practice. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 599-607.	2.8	32
88	Gut microbiota: sculptors of the intestinal stem cell niche in health and inflammatory bowel disease. Gut Microbes, 2021, 13, 1990827.	9.8	32
89	Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn's disease: Case report and systematic literature review. Journal of Crohn's and Colitis, 2008, 2, 337-342.	1.3	31
90	Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. Journal of Crohn's and Colitis, 2015, 9, 738-746.	1.3	31

6

#	Article	IF	CITATIONS
91	Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 305-316.	8.1	31
92	Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and postâ€marketing data. Alimentary Pharmacology and Therapeutics, 2020, 51, 149-157.	3.7	31
93	The management of mild to severe acute ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2004, 20, 88-92.	3.7	30
94	Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2021, 53, 568-576.	3.7	30
95	Unexplained gastrointestinal symptoms: Think mitochondrial disease. Digestive and Liver Disease, 2014, 46, 1-8.	0.9	29
96	Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation. Journal of Crohn's and Colitis, 2018, 12, 1097-1103.	1.3	29
97	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. Gastrointestinal Endoscopy, 2018, 88, 360-369.e2.	1.0	29
98	Remission of Inflammatory Bowel Disease in Glucose-6-Phosphatase 3 Deficiency by Allogeneic Haematopoietic Stem Cell Transplantation. Journal of Crohn's and Colitis, 2020, 14, 142-147.	1.3	27
99	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Inflammatory Bowel Diseases, 2020, 26, 1562-1571.	1.9	27
100	Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. Inflammatory Bowel Diseases, 2015, 21, 1.	1.9	26
101	Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians. Transfusion, 2011, 51, 1940-1948.	1.6	25
102	Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis. Journal of Crohn's and Colitis, 2020, 14, 1446-1461.	1.3	25
103	Gut microbiome diversity in acute severe colitis is distinct from mild to moderate ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 731-739.	2.8	25
104	Placebo Response Rate in Clinical Trials of Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2014, 12, 1981-1990.	4.4	24
105	The future of inflammatory bowel disease management: Combining progress in trial design with advances in targeted therapy. Journal of Crohn's and Colitis, 2012, 6, S250-S259.	1.3	23
106	Thrombosis in inflammatory bowel disease: Are we tailoring prophylaxis to those most at risk?. Journal of Crohn's and Colitis, 2014, 8, 166-171.	1.3	23
107	What's app? Electronic health technology in inflammatory bowel disease. Intestinal Research, 2018, 16, 366.	2.6	22
108	Correlation Between Endoscopic and Histological Activity in Ulcerative Colitis Using Validated Indices. Journal of Crohn's and Colitis, 2018, 12, 1151-1157.	1.3	22

#	Article	IF	CITATIONS
109	Advances in therapeutic approaches to ulcerative colitis and crohn's disease. Current Gastroenterology Reports, 2005, 7, 475-484.	2.5	21
110	Poor Outcomes in Hospitalized Patients With Gastrointestinal Bleeding: Impact of Baseline Risk, Bleeding Severity, and Process of Care. American Journal of Gastroenterology, 2014, 109, 1603-1612.	0.4	21
111	Predictors of longâ€ŧerm outcomes in patients with acute severe colitis: A northern Indian cohort study. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 615-622.	2.8	21
112	Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. Gut, 2020, 69, 658-664.	12.1	21
113	Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey. Inflammatory Bowel Diseases, 2021, 27, 836-847.	1.9	21
114	Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials. Journal of Crohn's and Colitis, 2018, 12, 905-919.	1.3	20
115	IBD2020 global forum: results of an international patient survey on quality of care. Intestinal Research, 2018, 16, 537-545.	2.6	20
116	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Nature Communications, 2022, 13, 1251.	12.8	20
117	Predicting the Individual Risk of Acute Severe Colitis at Diagnosis. Journal of Crohn's and Colitis, 2017, 11, jjw159.	1.3	19
118	Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. Journal of Crohn's and Colitis, 2017, 11, 246-255.	1.3	19
119	The role of a defunctioning stoma for colonic and perianal Crohn's disease in the biological era. Scandinavian Journal of Gastroenterology, 2017, 52, 251-256.	1.5	19
120	Diagnostic Yield of Dysplasia in Polyp-adjacent Biopsies for Patients with Inflammatory Bowel Disease: A Cross-sectional Study. Journal of Crohn's and Colitis, 2018, 12, 670-676.	1.3	19
121	'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?. Intestinal Research, 2015, 13, 227.	2.6	19
122	Predicting outcome in severe ulcerative colitis. Digestive and Liver Disease, 2004, 36, 448-449.	0.9	18
123	Central Endoscopy Reading in Inflammatory Bowel Diseases: Table 1 Journal of Crohn's and Colitis, 2016, 10, S542-S547.	1.3	18
124	Interfering with leukocyte trafficking in Crohn's disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 38-39, 101617.	2.4	18
125	Autologous stem cell transplantation in refractory Crohn's disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. BMC Gastroenterology, 2019, 19, 82.	2.0	17
126	Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia. Rheumatology, 2020, 59, 2166-2168.	1.9	17

#	Article	IF	CITATIONS
127	Improving the quality of care for inflammatory bowel disease. Intestinal Research, 2019, 17, 45-53.	2.6	17
128	Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World Journal of Gastroenterology, 2020, 26, 4428-4441.	3.3	16
129	Recent advances in immunomodulation in the treatment of inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2003, 15, 215-218.	1.6	14
130	The role of blood transfusion in the management of upper and lower intestinal tract bleeding. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 355-371.	2.4	14
131	Inflammatory Bowel Disease in Patients with Congenital Chloride Diarrhoea. Journal of Crohn's and Colitis, 2021, 15, 1679-1685.	1.3	14
132	The gut microbiota as a therapeutic target for obesity: a scoping review. Nutrition Research Reviews, 2022, 35, 207-220.	4.1	14
133	Endoscopic Disease Activity in Inflammatory Bowel Disease. Current Gastroenterology Reports, 2015, 17, 50.	2.5	13
134	Prevalence and longâ€ŧerm outcome of sub linical primary sclerosing cholangitis in patients with ulcerative colitis. Liver International, 2020, 40, 2744-2757.	3.9	13
135	Overexpression of Cancer-Associated Stem Cell Gene <i>OLFM4</i> in the Colonic Epithelium of Patients With Primary Sclerosing Cholangitis. Inflammatory Bowel Diseases, 2021, 27, 1316-1327.	1.9	13
136	Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation. Nature Communications, 2021, 12, 6702.	12.8	13
137	Colon salvage therapy for acute severe colitis: cyclosporine or infliximab?. Current Opinion in Gastroenterology, 2011, 27, 358-362.	2.3	12
138	Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, jjw174.	1.3	12
139	Diagnostic Accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for Lesion Characterization in Ulcerative Colitis. Journal of Crohn's and Colitis, 2018, 12, 1438-1447.	1.3	12
140	Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?. Intestinal Research, 2018, 16, 209.	2.6	12
141	The impact of intestinal transplantation on quality of life. Clinical Nutrition, 2020, 39, 1958-1967.	5.0	12
142	Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis. Intestinal Research, 2019, 17, 365-374.	2.6	12
143	An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. Journal of Crohn's and Colitis, 2009, 3, 32-37.	1.3	10
144	Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Current Medical Research and Opinion, 2021, 37, 1891-1900.	1.9	10

#	Article	IF	CITATIONS
145	Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn's disease patients: the METRIC diagnostic accuracy study. Health Technology Assessment, 2019, 23, 1-162.	2.8	10
146	Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study. Intestinal Research, 2018, 16, 69.	2.6	10
147	Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, Southâ€East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Diseaseâ€Emerging Nations' Consortium. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1004-1015.	2.8	10
148	An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. Journal of Crohn's and Colitis, 2009, 3, 168-174.	1.3	9
149	Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic. Gut, 2021, 70, 2398-2400.	12.1	9
150	High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis. Intestinal Research, 2021, 19, 438-447.	2.6	9
151	Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterology, 2022, 9, e000853.	2.7	9
152	Which 5-ASA?. Gut, 2002, 51, 548-549.	12.1	8
153	Does it all ADA up? Adalimumab for ulcerative colitis. Gut, 2011, 60, 741-742.	12.1	8
154	Short―and longâ€ŧerm outcomes of strictureplasty for obstructive Crohn's disease. Colorectal Disease, 2020, 22, 1159-1168.	1.4	8
155	Using item response theory (IRT) to improve the efficiency of the Simple Clinical Colitis Activity Index (SCCAI) for patients with ulcerative colitis. BMC Gastroenterology, 2021, 21, 132.	2.0	8
156	Does Smoking Cessation Reduce Surgical Recurrence After Primary Ileocolic Resection for Crohn's Disease?. Diseases of the Colon and Rectum, 2020, 63, 200-206.	1.3	8
157	Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis. Crohn's & Colitis 360, 2022, 4, .	1.1	8
158	Assessing disease activity in patients with ulcerative colitis. Gastroenterology and Hepatology, 2012, 8, 751-4.	0.1	7
159	IM-UNITI at Three Years: Stellar Stelara® or Stardust? The Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. Journal of Crohn's and Colitis, 2020, 14, 1-3.	1.3	6
160	Stress-related consequences of the coronavirus disease 2019 pandemic on symptoms of Crohn's disease. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, 1511-1516.	1.6	6
161	Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scandinavian Journal of Gastroenterology, 2021, , 1-8.	1.5	6
162	Prospective validation of AIIMS index as a predictor of steroid failure in patients with acute severe ulcerative colitis. Indian Journal of Gastroenterology, 2022, 41, 273-283.	1.4	6

#	Article	IF	CITATIONS
163	What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 564-565.	1.7	5
164	554 Correlation Between the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Outcomes in Acute Severe Ulcerative Colitis. Gastroenterology, 2013, 144, S-102.	1.3	5
165	New thinking: theory vs practice. A case study illustrating evidence-based therapeutic decision making. Colorectal Disease, 2006, 8, 25-29.	1.4	4
166	Exposure to hookworms in patients with Crohn's disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 1248-1249.	3.7	4
167	Does Disease Extent Matter when Scoring the UCEIS?. Journal of Crohn's and Colitis, 2015, 9, 694-694.	1.3	4
168	Conduct of Clinical Trials in UC. American Journal of Gastroenterology, 2006, 101, S429-S430.	0.4	4
169	Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region. Alimentary Pharmacology and Therapeutics, 2021, 53, 390-399.	3.7	4
170	Induction of remission with oral budesonide MMX® (9 mg) tablets in oatients with mild to moderate, active Ulcerative Colitis: A multicenter, open-label efficacy and safety study. Inflammatory Bowel Diseases, 2011, 17, S20.	1.9	3
171	Tu1106 Observer Agreement and Construct Validity in Central Endoscopic Assessment of Disease Activity in Ulcerative Colitis. Gastroenterology, 2013, 144, S-763.	1.3	3
172	The Crohn's Disease–Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. Clinical Gastroenterology and Hepatology, 2016, 14, e121-e122.	4.4	3
173	Potential of Fecal Calprotectin as an Objective Marker to Discriminate Hospitalized Patients with Acute Severe Colitis from Outpatients with Less Severe Disease. Digestive Diseases and Sciences, 2018, 63, 2747-2753.	2.3	3
174	Establishment of a validated central reading system for ileocolonoscopy in an academic setting. Gut, 2022, 71, 661-664.	12.1	3
175	Dose escalation of 5ASA: does it work?. Digestive and Liver Disease, 2005, 37, 82-84.	0.9	2
176	Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. The Cochrane Library, 2015, , .	2.8	2
177	The pediatric ulcerative colitis activity index (PUCAI) predicts steroid-failure in adults with acute severe colitis. Scandinavian Journal of Gastroenterology, 2021, 56, 1049-1055.	1.5	2
178	Patient-reported Goals in Inflammatory Bowel Disease: What's the Problem?. Journal of Crohn's and Colitis, 2022, 16, 339-340.	1.3	2
179	Foreword from the Chairman. Alimentary Pharmacology and Therapeutics, 2008, 27, v-v.	3.7	1

0.4 1

#	Article	IF	CITATIONS
181	Is Crohn's Disease a Rightly Used Eponym?. Journal of Crohn's and Colitis, 2020, 14, 867-871.	1.3	1
182	P127â€Real world effectiveness of ustekinumab for refractory Crohn's disease: a regional experience. , 2021, , .		1
183	The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis. Intestinal Research, 2023, 21, 161-167.	2.6	1
184	Response to Villanacci et. al Journal of Crohn's and Colitis, 2015, 9, 429-429.	1.3	0
185	Swallowing anti-TNFÎ $\pm$ in Ulcerative Colitis: Potentially More Gain Than Pain. Journal of Crohn's and Colitis, 2016, 10, 629-630.	1.3	0
186	Editorial: gut selective immunosuppression—is it a double edged sword? Authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 374-374.	3.7	0
187	Endoscopy in Inflammatory Bowel Disease: Western Perspective—Europe. , 2018, , 275-282.		0
188	Authors' reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn's Disease Behavior, Fecal Calprotectin and Quality of Life. Inflammatory Bowel Diseases, 2019, 25, e62-e63.	1.9	0
189	P106â€Prediction of outcome in acute severe ulcerative colitis – comparison of clinical and endoscopic indices. , 2021, , .		0
190	P107â€Changing outcomes in acute severe ulcerative colitis at Oxford in last seven decades. , 2021, , .		0
191	Assessment of Disease Activity in Ulcerative Colitis. , 2014, , 345-357.		0
192	OFR-10â€Admission model for intensification of therapy in acute severe colitis (ADMIT-ASC). , 2021, , .		0
193	Editorial: is enteral nutrition back in acute severe ulcerative colitis? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 747-748.	3.7	0